Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avelumab + azacitidine
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
avelumab + azacitidine is a combination therapy regimen investigated by the M.D. Anderson Cancer Center for the treatment of relapsed or refractory acute myeloid leukemia (AML). The regimen pairs avelumab, a human anti-PD-L1 IgG1 monoclonal antibody, with azacitidine, a hypomethylating agent. Avelumab functions as an immune checkpoint inhibitor by blocking the interaction between PD-L1 on tumor cells and PD-1 on T-cells, thereby restoring anti-tumor immune activity. Azacitidine, a pyrimidine nucleoside analog, incorporates into DNA and inhibits DNA methyltransferases, leading to hypomethylation and the reactivation of tumor suppressor genes, while also exerting direct cytotoxic effects on hematopoietic cells. In clinical studies, the combination was found to be well-tolerated but demonstrated limited clinical efficacy in the relapsed/refractory AML setting.
- Other names
- A-M.D. Anderson Cancer Center-leukemia (acute myeloid)Avelumab and Azacitidine in Refractory/Relapsed AML
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)DNMT3A (DNA methyltransferase 3 alpha)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on avelumab + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avelumab + azacitidine.